Targeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in hepatocellular carcinoma - PubMed
4 hours ago
- #Nrf2 inhibition
- #Immunotherapy
- #Hepatocellular Carcinoma
- Targeted inhibition of Nrf2 enhances antitumor immunity and improves immunotherapy efficacy in hepatocellular carcinoma (HCC).
- Brusatol (BRU), a specific Nrf2 inhibitor, downregulates PD-L1 and upregulates MHC-I in tumor cells, promoting CD8+ T-cell infiltration.
- Combining Nrf2 inhibition with anti-PD-1 antibody or CAR-T cell therapy significantly boosts HCC treatment outcomes in vivo.
- The study suggests Nrf2 blockade as a novel strategy to overcome resistance and improve response rates in HCC immunotherapy.